

HEMOCLOT VII-X

ACK051K-RUO

Measurement of Factor VII + X with a clotting method

**FOR RESEARCH USE ONLY.
NOT FOR USE IN DIAGNOSTIC PROCEDURES**



Manufactured By: HYPHEN BioMed

Last revision : 28/04/2011

1. Intended use:

The **HEMOCLOT VII-X** kit is proposed for the measurement of Factors VII+X activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. **This kit is for research use only and should not be used for patient diagnosis or treatment.**

2. Assay principle:

The **HEMOCLOT VII-X** method is a clotting assay where all the extrinsic pathway clotting factors are present and in excess, excepted for factors VII and X, which are brought by the diluted tested plasma, and thromboplastin.

Factors VII and X are the limiting factors and clotting time is inversely proportional to the concentration of factors VII and X. There is an inverse linear relationship, on a bilogarithmic graph paper, between the factor VII-X concentration and the corresponding clotting time.

3. Assay specimen:

Human plasma obtained from Trisodium Citrate anticoagulated blood.

4. Reagents:

Each kit contains:

- 6 vials of 1 ml of **HEMOCLOT VII-X** reagent, a clotting mixture containing highly purified bovine prothrombin, fibrinogen and Factor V, lyophilized in presence of preservatives and stabilizers.

5. Reagents and material required, but not supplied:

- Pipettes with dispensing volumes of 20 µl, 50 µl and 100 µl.
- Pipette with a variable dispensing volume from 50 µl to 1,000 µl.
- Semi-automatic or automatic coagulation instrument, or fibrometer or electromagnetic water bath.
- Distilled water.
- Imidazole buffer (# AAR021A/AAR021K/AAR021L).
- Normal pool human plasma or Factors VII + X calibrator (BIOPHEN Plasma Calibrator - # A222101).
- Normal and Abnormal control plasmas, titrated for factors VII+X, (BIOPHEN Normal Control Plasma - #A223201 and BIOPHEN Abnormal Control Plasma - #A223301).
- Calcium Thromboplastin (such as rabbit brain thromboplastin).

6. Reagent preparation and stability:

In their original package, and before any use, when stored at 2-8°C, the **HEMOCLOT VII-X** reagent is stable until the expiration date printed on the kit.

• Reagent Preparation:

Hemoclot VII-X: Restore the Hemoclot VII-X vial with 1 ml of distilled water; let for 15 min. at room temperature; mix gently until complete dissolution of the content.

• Reagent stability following reconstitution:

- 24 hours at room temperature (18-25°C).
- 72 hours at 2-8°C.
- 1 month frozen at -20° or below.

Note: Source bovine plasma used for the extraction of proteins included in the preparation of **HEMOCLOT VII-X** were tested with registered methods and found negative for bovine infectious diseases, notably for the bovine spongiform encephalopathy. However, no assay may warrant the total absence of infectious agents. Any product of bovine origin must then be handled with all the required cautions, as being potentially infectious.

7. Sample collection and preparation:

Blood (9 vol.) must be collected on 0.109M trisodium citrate anticoagulant (1 vol.); plasma supernatant is decanted following a 20 min. centrifugation at 2,500 g; citrated plasma must be tested within 8 hours when stored at room temperature (18-25°C), or can be used within 24 hours if kept at 2-8°C, or it can be frozen at -20°C or below for up to 6 months. Just before use, the plasma must be thawed for 15 min. in a water bath at 37°C. Thawed plasma must be used within 4 hours, at room temperature (18-25°C).

8. Protocol:

• Calibration curve:

Prepare 2 ml of normal citrated human pooled plasma **diluted 1:10** in Imidazole buffer. By definition, this ten fold dilution of the normal citrated human plasma pool corresponds to a concentration of **100% of factors VII + X**. Using this preparation, the calibration curve is obtained as follows:

VII-X	0%	12.5%	25%	50%	100%
Dilution	0	1:80	1:40	1:20	1:10
Plasma pool 1:10	0 mL	0.125 mL	0.250 mL	0.500 mL	1 mL
Imidazole Buffer	1 mL	0.875 mL	0.750 mL	0.500 mL	0 mL

The calibration curve must be used within 4 hours at room temperature.

The calibration curve can also be established with the BIOPHEN Plasma Calibrator (#A222101), using the factor VII-X activity indicated on the flyer for the lot used.

• Preparation of tested plasma:

Tested plasma must be **diluted 1:10** in Imidazole type buffer. The diluted plasma must be tested within 4 hours.

D.750.02/CK/051K/RUO



7768 Service Center Drive • West Chester OH 45069

Phone: 513.770.1991

Toll Free: 866.783.3797

Fax: 513.573.9241

Email: info@aniara.com

www.aniara.com

- **Assay:**

Manual Method:

Preincubate Calcium Thromboplastin at 37°C.

In a test tube, or a cuvette, introduce:

- 100 µl of **HEMOCLOT VII-X** reagent.
- 100 µL of calibration solution or of tested plasma diluted **1:10**.

Incubate for 1 to 2 min. at 37°C, and then introduce:

- 150 µl of Calcium Thromboplastin preincubated at 37°C.

Record the clotting time.

Automatic Method:

The assay can be used with the semi-automatic or automatic instruments, such as ACL, STA, STA-R, KC-4, KC-10, BCT, BCS, etc...

The usual program used for testing the factors involved in the extrinsic pathway with a clotting based calcium thromboplastin method, and a specific deficient plasma, can be applied. The respective specimen and reagent volume ratios indicated for the manual method must be strictly respected. Usually, with automatic methods the volumes used for reagents and tested plasma (diluted 1:10) are half those recommended for the normal method.

With semi automatic or automatic instruments, especially those with a photometric detection of clot formation, clotting times use to be slightly shorter than with the manual method.


9. Expression of results:

On a bilogarithmic graph paper, plot on abscissae the VII + X concentrations and on ordinates the corresponding clotting times. On the calibration curve obtained, interpolate directly the corresponding VII+X concentration for the tested plasma.

The results obtained should be for research purposes only and not used for patient diagnosis or treatment.

Example of Calibration curve:

This calibration curve is indicated as an example only. It was obtained with Calcium Thromboplastin (Calcic Thromboplastin) from Biomerieux (69-Marcy-l'Etoile-France), using a manual method.



10. Interferences:

The **HEMOCLOT VII-X** reagents **do not contain heparin inhibitors**. Presence of heparin or of other anti-thrombin or anti-Xa substances may interfere in the assay and prolong the clotting time.

However, current Calcium Thromboplastin preparations use to contain an heparin inhibitor. The assay is then insensitive to the presence of heparin. If any risk of interference of heparin must be avoided, check that the Calcium Thromboplastin used contains a heparin inhibitor. However, heparin inhibitors, present in thromboplastin preparations, are not always totally efficient for neutralizing Low Molecular Weight Heparin (LMWH).

11. Assay variations:

The clotting times observed for this assay are obtained with Calcium Thromboplastin from Biomerieux (Calcic Thromboplastin) or from Diagnostica Stago (Neoplastin). They are in the range from 25 to 35 seconds for the 100% VII+X concentration. Higher clotting times are obtained with other thromboplastins, such as PT-Fibrinogen, from IL. The assay performances can slightly vary according to the thromboplastin reagent type and lot, and the instrument used in the laboratory. Performances, as well as target values and acceptance ranges for each new lot of quality controls used, must then be confirmed (and adjusted if necessary) in the laboratory working conditions.

12. References:

1. Soulier JP, Larrieu MJ. Etude analytique des temps de Quick allongés. Dosage de prothrombine, de proconvertine et de proaccélélerine. Sang 1952 ; 23: 549-559.
2. Favre-Gilly J, Belleville J, Croizat P, Revel L. Les états hémorragiques acquis par trouble plasmatique de coagulation. Cah Med Lyonnais 1967 ; 43 (28) : 2611-2668.
3. Gjonnaess H, Fagerhol MK. Studies on coagulation and fibrinolysis in pregnancy. Acta Obste Gynecol Scand 1975; 54: 363-367.
4. Andrew M, Paes B, Milner R, Hohnston M, Mitchell L, Tollefsen DM, Powers P. Development of the human coagulation system in the full-term infant. Blood 1987; 70: 165-172.